In ₹ Crore except Per Share Latest Annual	KPL FY24	BPLPHARMA FY23	JENBURPH FY26	MAKERSL FY26	Peer Average
Valuation — at last close
P/E	—	45.39×	—	—	45.39×
P/B	—	5.78×	—	◆ 2.05×	3.92×
EV/EBITDA	—	◆ 51.68×	—	156.70×	104.19×
Market Cap	—	₹1,105 Cr	—	₹112 Cr	₹608 Cr
Growth
Revenue CAGR 3Y	—	—	◆ 7.26%	5.77%	6.51%
Revenue CAGR 5Y	—	—	◆ 9.07%	1.55%	5.31%
Net Income CAGR 3Y	—	—	12.18%	—	12.18%
Profitability
EBITDA Margin	21.69%	9.80%	◆ 23.81%	1.45%	11.69% +86%
Net Income Margin	—	11.16%	◆ 20.59%	-3.42%	9.44%
Return on Common Equity	—	13.63%	◆ 18.84%	-3.11%	9.79%
Return on Capital Employed	19.78%	—	—	—	—
Return on Assets	—	9.25%	◆ 16.45%	-2.37%	7.78%
Credit & Quality
Total Debt/Equity	0.43×	◆ 0.04×	—	0.05×	0.04× +856%
Interest Coverage	4.54×	◆ 7.10×	—	-3.91×	1.59× +185%
Scale — latest FY
Revenue / Total Income	₹307 Cr	₹218 Cr	₹169 Cr	₹50.3 Cr	₹146 Cr +111%
Net Income	—	₹24.3 Cr	₹34.7 Cr	−₹1.7 Cr	₹19.1 Cr
Total Assets	₹398 Cr	₹308 Cr	₹226 Cr	₹73.5 Cr	₹203 Cr +96%
EPS	—	₹42.14	—	₹-2.91	₹19.62
Book Value per Share	—	₹330.83	—	₹92.11	₹211.47

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.